This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

AMPLATZER Cardiac Plug (ACP) Registry-Long Term Follow-up Protocol (ACPR)

This study has been completed.
Information provided by (Responsible Party):
St. Jude Medical Identifier:
First received: January 29, 2013
Last updated: September 19, 2016
Last verified: September 2016
The objective of the AMPLATZER Cardiac Plug (ACP) Registry Long Term Follow-up study is to evaluate long term performance of the ACP in closure of the Left Atrial Appendage (LAA) in subjects with nonvalvular atrial fibrillation and assess adverse events up to two (2) or more years post implant.

Condition Intervention
Atrial Fibrillation Left Atrial Appendage Stroke Device: Amplatzer Cardiac Plug

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration: 4 Years

Resource links provided by NLM:

Further study details as provided by St. Jude Medical:

Primary Outcome Measures:
  • The rate of occurrence for any reported adverse event experienced by subjects enrolled. [ Time Frame: Through 2 years ]
  • Closure [ Time Frame: 6 months ]
    Defined as absence of flow or flow of ≤3mm jet into the LAA at procedure and at six (6) months as assessed by Transoesophageal Echocardiography (TOE).

  • Technical success [ Time Frame: At implant ]
    Defined as delivery and release of the ACP device, including recapture and/or replacement, as necessary. This success will be calculated among subjects in whom the device enters the body

Enrollment: 204
Study Start Date: August 2009
Study Completion Date: January 2014
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Delivery system entry Device: Amplatzer Cardiac Plug


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with non-valvular atrial fibrillation

Inclusion Criteria:

  • Subject must have a documented history of paroxysmal, persistent or permanent nonvalvular atrial fibrillation (documentation may include an electrocardiogram (ECG), Holter, or event recorder)
  • Subject must be ≥18 years of age

Exclusion Criteria:

  • Subject with an implanted atrial septal defect (ASD) device or patent foramen ovale (PFO) device
  • Subject who has a history of surgical ASD or PFO repair
  • Subject with a history of stroke and unrepaired PFO
  • Subject who has moderate to severe aortic or mitral valve stenosis or regurgitation as assessed by the investigator
  • Subject who has a mitral or aortic prosthetic valve
  • Subject who has a planned ablation procedure for atrial fibrillation 30 days after the ACP implant
  • Subject with New York Heart Association (NYHA) grade 4
  • Subject with evidence of pericardial effusion at baseline evaluation
  • Subject who has complex atheroma with mobile plaque of the descending aorta and/or aortic arch
  • Subject who has an intracardiac thrombus
  • Subject who has carotid disease as assessed by the investigator, requiring treatment, which includes revascularization and/or medical treatment
  • Subject with active infection or active endocarditis
  • Subject who has an acute or recent myocardial infarction (MI) or unstable angina (recent is defined as within 6 months of implant date)
  • Subject who has had recent major cardiac surgical procedure (recent is defined as within 6 months of implant date)
  • Subject with malignancy or other illness where life expectancy is less than one year
  • Subject who is pregnant, breastfeeding, or desires to become pregnant during their first six months of follow-up
  • Subject or legally authorized representative who is unable to provide informed consent
  • Subject who will not be able to be followed for the duration of the clinical study
  • Subject with any medical disorder or severe disability that would interfere with completion or evaluation of clinical study results (for e.g. uncontrolled hypertension, uncontrolled diabetes, renal failure, in situ inferior vena cava (IVC) filter)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01786486

Czech Republic
Hospital Na Homolce Cardiocentrum
Prague, Czech Republic
St. Marien-Hospital Bonn
Bonn, Germany
University of Bonn
Bonn, Germany
Cardiovascular Center Frankfurt
Frankfurt, Germany
Kardiocentrum Frankfurt an der Klinik Rotes Kreuz
Frankfurt, Germany
University Medicine Goettingen
Goettingen, Germany
Asklepios Kliniken GmbH/Asklepios Klinik Harburg
Hamburg, Germany
Stadt Krankenhaus Pirmasens gGmbh
Pirmasens, Germany
Mater Misericordiae University Hospital
Dublin, Ireland
Hospital Universitario Infanta Cristina
Badajoz, Spain
Hospital Clinico San Carlos
Madrid, Spain
Hospital Universitario 'Virgen de la Arrixaca"
Murcia, Spain
Hospital de Navarra
Pamplona, Spain
United Kingdom
Royal Sussex County Hospital-UK
Brighton, United Kingdom
John Radcliffe Hospital
Oxford, United Kingdom
Sponsors and Collaborators
St. Jude Medical
  More Information

Responsible Party: St. Jude Medical Identifier: NCT01786486     History of Changes
Other Study ID Numbers: CL03562
Study First Received: January 29, 2013
Last Updated: September 19, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Manuscript has been submitted to Euro Intervention Sept 2016

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes processed this record on September 21, 2017